Argos Therapeutics (ARGS) Misses Q3 EPS by 5c

Argos Therapeutics (NASDAQ: ARGS) reported Q3 EPS of ($0.97), $0.05 worse than the analyst estimate of ($0.92). Revenue for the quarter came in at $158.35 thousand versus the consensus estimate of $230 thousand.

For earnings history and earnings-related data on Argos Therapeutics (ARGS) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Zeo Energy Corp (ZEO) Misses Q2 EPS by 7c
• Reading (RDI) Tops Q2 EPS by 4c